GlassScriptPhysician profile
Sonia Garcia
NPI 1992046296
$5,699.00
in general payments reported to CMS, 2019-2025
21 companies · $989 in 2025
The $989 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $604 · 2022: $1,683 · 2023: $1,490 · 2024: $934 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,412.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $2,062.10 | 2022-2025 | Nuplazid |
| Abbvie INC. | $585.69 | 2021-2025 | |
| Alkermes, INC. | $441.92 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $414.75 | 2021-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $360.10 | 2022-2025 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $322.78 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $311.16 | 2021-2023 | Spravato, Invega Trinza, Invega |
| Otsuka America Pharmaceutical, INC. | $268.27 | 2021-2025 | Rexulti, Abilify Maintena |
| Cmp Pharma, INC. | $144.03 | 2021-2023 | Carospir, Norliqva, Tadliq |
| Takeda Pharmaceuticals U.S.A., INC. | $125.30 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.81 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.86 | 2022 | |
| Neuronetics, INC. | $105.19 | 2022-2023 | Neurostar Tms Therapy System |
| Lundbeck LLC | $60.39 | 2022-2024 | Rexulti |
| Corium, LLC | $57.09 | 2022-2023 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $55.18 | 2022-2024 | Perseris |
| Alpha Cognition USA, INC. | $47.95 | 2025 | Zunveyl |
| Sunovion Pharmaceuticals INC. | $44.83 | 2021 | |
| Lilly USA, LLC | $30.96 | 2025 | Zepbound |
| Veloxis Pharmaceuticals, INC. | $24.48 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.